The Newsroom

Investigations  /  12.21.2020

Investigation of Sona Nanotech Inc.

You Have Legal Options

Sona Nanotech Inc. (SNANF) Misled Shareholders Regarding the Viability of its Rapid, COVID-19 Antigen Test      

On July 2, 2020, Sona issued a press release announcing that its rapid detection, COVID-19 antigen test was entering into an independent clinical, in-field evaluation study to generate data to support its submission to the FDA and Health Canada for emergency use authorization.  Sona stated that the results from the field study would be available at the end of July.  On August 6, 2020, Sona published a press release updating the status of its COVID-19 antigen test, and stating there would be a delay in the results due to study modifications and ethics review board approvals.  On this news, shares of Sona fell $3.09 per share, or over 34%, on August 6, 2020.  Then, on October 29, 2020, Sona issued a press release announcing that it had received notice from the FDA that the Company’s request for an emergency use authorization for the marketing of its rapid, COVID-19 antigen test in the U.S. “is not a priority” and would not be issued.  On this news, shares of Sona fell $2.77 per share, or over 48%, to just $3.00 on October 29, 2020.  On November 25, 2020, Sona’s stock fell again, closing at just $0.74 per share, on Sona’s announcement that it withdrew its application for an Interim Order authorization from Health Canada for the marketing of its rapid, COVID-19 antigen test to obtain more clinical data to augment its submission.

 If you purchased your Sona Nanotech Inc. (SNANF) between July 2, 2020 and November 25, 2020, you have until February 16, 2021, to ask the court to appoint them as lead plaintiff for the class

  • If you would like more information about your rights and potential remedies please send us a message. 

  • Please Note: Neither the submission to nor the receipt of information by Robbins LLP or one of its attorneys through this website constitutes an agreement by our firm to represent the individual and does not create an attorney-client relationship. Please do not send confidential or sensitive information through this website. This information should be communicated through a direct contact with an individual at the firm.


How can we help you?

CONTACT US TODAY | 1 800 350 6003 or [email protected]

Tell us your concerns